Quince Therapeutics, INC

Quince Therapeutics is holding a special meeting for stockholders to approve share issuances related to convertible preferred stock and warrants, impacting ownership and potentially control.

Quince Therapeutics reported Q2 2026 results, highlighting the acquisition of Orphai Therapeutics, a $115 million private placement, and advancements in its LAM-001 program for pulmonary diseases.

Quince Therapeutics announces conditional resignations of CEO Dirk Thye and COO Brendan Hannah, with Brigette Roberts and John Militello conditionally appointed to lead.

Quince Therapeutics has completed the acquisition of Orphai Therapeutics, integrating Orphai's lead asset LAM-001, an inhaled rapamycin formulation, into its pipeline for treating serious pulmonary disorders.

Quince Therapeutics has finalized a 1-for-20 reverse stock split effective June 29, 2026, to consolidate its common shares.

Quince Therapeutics will implement a 1-for-20 reverse stock split effective June 29, 2026, to consolidate its outstanding common shares.

Quince Therapeutics reported disappointing Phase 3 trial results for eDSP, leading to the discontinuation of its development and a pivot towards exploring strategic alternatives, including a potential reverse merger.

Quince Therapeutics reported increased net losses and R&D expenses for Q3 2025, raising substantial doubt about its ability to continue as a going concern despite clinical trial progress and recent financing.

Quince Therapeutics reports progress in its Phase 3 A-T trial and secures a strategic partnership, but faces substantial doubt about its ability to continue as a going concern.

Quince Therapeutics reports a net loss of $15.03 million for Q1 2025 and expresses substantial doubt about its ability to continue as a going concern due to insufficient funding.

Quince Therapeutics' Q3 2024 report highlights progress in the EryDex Phase 3 trial, alongside financial updates and a waiver of a key debt covenant.

Quince Therapeutics reported its second quarter 2024 results, including a significant goodwill impairment charge, while also highlighting progress in its Phase 3 clinical trial for EryDex.

Quince Therapeutics announced the discontinuation of its eDSP program for A-T due to unsuccessful Phase 3 trial results and is now exploring strategic alternatives, including a reverse merger.

Quince Therapeutics details its 2024 activities, highlighting the Phase 3 NEAT trial for eDSP in A-T and strategic focus on rare disease treatments.

Quince Therapeutics, Inc. released its 10-K filing for fiscal year 2023, highlighting its strategic shift towards rare disease therapeutics and the advancement of its lead asset, EryDex.

Quince Therapeutics director David Lamond was granted 2,700 stock options as part of a standard equity compensation package.

Director Christopher J. Senner was granted 2,700 stock options in Quince Therapeutics, Inc. as part of a standard equity compensation arrangement.

Chief Corporate Affairs Officer Brigette Roberts reports the exchange of Orphai Therapeutics stock options for Quince Therapeutics options following a merger.

Quince Therapeutics' CEO and CMO, Dirk Thye, was granted 1,000,000 employee stock options with an exercise price of $3.08, vesting monthly through December 2029.

Quince Therapeutics President Charles S. Ryan acquired 200,000 employee stock options with an exercise price of $3.08, vesting through December 2029.

Brendan Hannah, Quince Therapeutics' CBO, COO, and CCO, was granted 365,000 employee stock options with an exercise price of $3.08.

Quince Therapeutics announces its 2026 Annual Meeting, seeking shareholder approval for a reverse stock split to maintain Nasdaq compliance.

Quince Therapeutics, Inc. has filed a definitive proxy statement with the SEC.

Quince Therapeutics is asking stockholders to approve an amendment to increase authorized shares and effect a reverse stock split at the upcoming annual meeting.

Quince Therapeutics, Inc. will hold its 2024 Annual Meeting virtually on June 5, 2024, and is asking stockholders to vote on key proposals, including a reverse stock split.

Quince Therapeutics announces its 2024 Annual Meeting of Stockholders to be held virtually on June 5, 2024, including proposals for director elections, a reverse stock split, auditor ratification, and executive compensation approval.

Ikarian Capital, LLC and Neil Shahrestani have reported beneficial ownership of 9.0% of Quince Therapeutics, Inc. common stock as of June 30, 2026.

Nantahala Capital Management, LLC and its principals, Wilmot B. Harkey and Daniel Mack, have reported a 0.00% beneficial ownership of Quince Therapeutics, Inc. common stock as of June 30, 2026.

Cormorant Asset Management, LP and Bihua Chen have reported a 9.99% beneficial ownership in Quince Therapeutics, Inc., primarily through convertible securities.

Balyasny Asset Management L.P. and affiliated entities have reported beneficial ownership of 9.99% of Quince Therapeutics, Inc. common stock as of June 30, 2026.

Squadron Master Fund LP, along with its investment advisor Squadron Capital Management LLC and key individuals, has reported beneficial ownership of 5.6% of Quince Therapeutics, Inc. common stock.

Millennium Management LLC and affiliated entities have reported a significant beneficial ownership stake of 7.2% in Quince Therapeutics, Inc.